Cerulean Pharma

Cambridge, United States Founded: 2006 • Age: 20 yrs Acquired By Daré Bioscience
Nanoparticle-drug conjugates are developed to target tumors and reduce toxicity.
Annual revenue - Latest available
Total funding $88.7M 11 rounds
Employees 20 Tracked headcount
Investors 8 Known backers
Products 3 Services tracked
Competitors 10 Brand Intelligence

About Cerulean Pharma

Cerulean Pharma is a company based in Cambridge (United States) founded in 2006 was acquired by Daré Bioscience in March 2017. Cerulean Pharma has raised $88.7 million across 11 funding rounds from investors including ARE, Bessemer Venture Partners and Daré Bioscience. The company has 20 employees as of December 31, 2016. Cerulean Pharma offers products and services including Prescription Medications, Over-the-Counter Drugs, and Generic Drugs. Cerulean Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter Cambridge, United States
  • Employees 20 as on 31 Dec, 2016
  • Stage Public
  • Sectors
    Technology
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cerulean Pharma Inc.
Operational Areas
Technology → Quantum & Emerging Technologies Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $88.7 M (USD)

    in 11 rounds

  • Latest Funding Round
    Not available
  • Investors
    ARE

    & 7 more

  • Employee Count
    20

    as on Dec 31, 2016

  • Acquired by
    Daré Bioscience

    (Mar 19, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cerulean Pharma

Cerulean Pharma offers a comprehensive portfolio of products and services, including Prescription Medications, Over-the-Counter Drugs, and Generic Drugs.

Product name locked
Category locked
Primary

Platform for ordering and delivering regulated prescription drugs securely.

Product name locked
Category locked
Locked

Sale of non-prescription items like vitamins and analgesics for daily use.

Product name locked
Category locked
Locked

Lower-cost alternatives to brand drugs for various health conditions.

Funding Insights of Cerulean Pharma

Cerulean Pharma has successfully raised a total of $88.7M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Cerulean Pharma

Cerulean Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Bessemer Venture Partners and Daré Bioscience.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture debt financing is provided to companies in multiple sectors.
Locked Locked Locked
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
Locked Locked Locked
Early-stage life sciences investments are targeted in the healthcare sector.
Locked Locked Locked
Premium access

Investor details for Cerulean Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cerulean Pharma

Investments
Premium access

Investment portfolio details for Cerulean Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Cerulean Pharma

Premium access

Detailed financials for Cerulean Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cerulean Pharma Comparisons

Cerulean Pharma Primary company
Description
Nanoparticle-drug conjugates are developed to target tumors ...
Location
Cambridge, United States
Founded Year
2006
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
20
As of 2016
Premium access

Peer comparison for Cerulean Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Cerulean Pharma

Cerulean Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Targeted and immune-oncology drugs for cancer treatment are developed.
Locked Locked Locked
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
Locked Locked Locked
Small molecules are developed for cancer and skin disease treatments.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Premium access

Detailed competitors of Cerulean Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cerulean Pharma

Premium access

Complete news archive for Cerulean Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cerulean Pharma

Cerulean Pharma was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Cerulean Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Cerulean Pharma is a funded company, having raised a total of $88.7M across 11 funding rounds to date.

As of Dec 31, 2016, the latest employee count at Cerulean Pharma is 20.

Cerulean Pharma, formerly Tempo Pharmaceuticals, is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The company has a Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the bodys normal cells, and enable therapeutic combinations.Their lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments as part of a combination therapy.

Cerulean Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

Cerulean Pharma offers Prescription Medications, Over-the-Counter Drugs, and Generic Drugs.

Cerulean Pharma has 8 investors. Key investors include ARE, Bessemer Venture Partners, Daré Bioscience, Hercules Capital, and Lilly Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available